Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Principia Biopharma Inc (PRNB)

Principia Biopharma Inc (PRNB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,322,560
  • Shares Outstanding, K 33,209
  • Annual Sales, $ 35,160 K
  • Annual Income, $ -53,790 K
  • 60-Month Beta 0.86
  • Price/Sales 94.40
  • Price/Cash Flow N/A
  • Price/Book 9.41
Trade PRNB with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.41
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/03/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.85
  • Number of Estimates 4
  • High Estimate 0.30
  • Low Estimate -1.42
  • Prior Year -0.93
  • Growth Rate Est. (year over year) +8.60%

Price Performance

See More
Period Period Low Period High Performance
1-Month
99.76 +0.29%
on 09/04/20
101.25 -1.19%
on 08/26/20
-1.02 (-1.01%)
since 08/25/20
3-Month
53.36 +87.50%
on 07/09/20
101.89 -1.81%
on 08/25/20
+40.58 (+68.24%)
since 06/25/20
52-Week
25.35 +294.67%
on 10/02/19
101.89 -1.81%
on 08/25/20
+69.41 (+226.53%)
since 09/25/19

Most Recent Stories

More News
Patient Enrollment Concluded Early in PEGASUS Phase 3 Pemphigus Trial for Rilzabrutinib

Principia Biopharma Inc., a Sanofi company, focused on developing treatments for immune mediated diseases, today announced it has completed patient enrollment into the global Phase 3 PEGASUS trial for...

PRNB : 100.05 (+0.10%)
Principia Announces First Patient Dosed in Phase 2A Trial of Rilzabrutinib in IgG4-Related Disease

Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune mediated diseases, today announced that the first patient was dosed in an open...

PRNB : 100.05 (+0.10%)
(PRNB) Alert: Johnson Fistel Investigates Proposed Sale of Principia Biopharma; Is $100 a Fair Price?

, /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Principia Biopharma Inc. ("Principia " or the "Company") (NASDAQ: PRNB) breached...

PRNB : 100.05 (+0.10%)
SNY : 51.13 (+1.85%)
Neoleukin Therapeutics Announces Appointment of Martin Babler to Board of Directors

Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the appointment...

NLTX : 13.45 (+5.57%)
PRNB : 100.05 (+0.10%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders are Encouraged to Contact the Firm - PRNB, BLDR, AKCA, YIN

, /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating:

PRNB : 100.05 (+0.10%)
BLDR : 37.93 (+1.61%)
AKCA : 18.17 (+0.17%)
YIN : 7.25 (+0.14%)
Moore Kuehn Encourages SBPH, PFNX, VAR, and PRNB Investors to Contact Law Firm

Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders....

SBPH : 1.2100 (unch)
PFNX : 12.75 (+0.08%)
VAR : 173.90 (-0.12%)
PRNB : 100.05 (+0.10%)
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of PRNB, CBMG, PFNX, and VAR Buyouts

Rigrodsky & Long, P.A. announces that it is investigating:

CBMG : 18.70 (+0.32%)
PRNB : 100.05 (+0.10%)
VAR : 173.90 (-0.12%)
Lifshitz Law Firm, P.C. Announces Investigation of Cancer Genetics, Inc., Momenta Pharmaceuticals, Inc., Principia Biopharma Inc., and Yintech Investment Holdings Limited

EQNX::TICKER_START (NASDAQ:CGIX),(NASDAQ:MNTA),(NASDAQ:PRNB),(NASDAQ:YIN), EQNX::TICKER_END

CGIX : 2.44 (+3.83%)
MNTA : 52.48 (+0.02%)
PRNB : 100.05 (+0.10%)
YIN : 7.25 (+0.14%)
WeissLaw LLP Reminds PFNX and PRNB Shareholders About Its Ongoing Investigations

, /PRNewswire/ --

PFNX : 12.75 (+0.08%)
PRNB : 100.05 (+0.10%)
MERGER ALERT - AIMT, PRNB, and BLDR: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies

NEW YORK, NY / ACCESSWIRE / September 1, 2020 / The following statement is being issued by Levi & Korsinsky, LLP:

AIMT : 34.49 (-0.29%)
PRNB : 100.05 (+0.10%)
BLDR : 37.93 (+1.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Principia Biopharma Inc. is a clinical stage biopharmaceutical company. It offers reversible covalent small molecule drugs for the treatment of cancers. The company's product pipeline consists of PRN1008, PRN1371 and PRN2246 which are in clinical stage. Principia Biopharma Inc. is based in San Francisco,...

See More

Key Turning Points

2nd Resistance Point 100.54
1st Resistance Point 100.30
Last Price 100.05
1st Support Level 99.88
2nd Support Level 99.70

See More

52-Week High 101.89
Last Price 100.05
Fibonacci 61.8% 72.65
Fibonacci 50% 63.62
Fibonacci 38.2% 54.59
52-Week Low 25.35

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar